Share this Page:
In this video interview Dr Chung-Han Lee from Memorial Sloan Kettering Cancer Centre in the USA discusses the positive results from the phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.
“Outcomes for late-line metastatic renal cell carcinoma are often poor using currently available medications with similar mechanism of action,” said Dr Chung-Han Lee. “New treatments with novel mechanisms of action are greatly needed for this patient population. The results from the randomised ENTRATA trial demonstrate activity of telaglenastat in RCC and provide proof of concept for glutaminase inhibition as a new mechanism of action that may improve outcomes for patients with this disease.”
Telaglenastat is currently also being looked at in the ongoing CANTATA trial in combination with cabozantinib for patients with advanced clear cell RCC.